A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial

Trials

Lars Bullinger¹  Johann Motsch²  Markus A. Weigand²  Ralf Bartenschlager³  Anna Plaszczyca³  Barbara Müller⁴  Hans-Georg Kräusslich⁴  Uta Merle⁵  Carsten Müller-Tidow⁶  Katharina Kriegsmann⁶  Maike Janssen⁶  Michael Schmitt⁶  Hanns-Martin Lorenz⁶  Tobias Liebregts⁶  Peter Dreger⁶  Jan Philipp Novotny⁶  Isabella Haberbosch⁶  Ulrike Schäkel⁶  Richard F. Schlenk⁷  Claudia M. Denkinger⁸  Stefan Weber⁸  Maria Vehreschild⁹  Stefan Meuer^1,10  Albrecht Leo^1,10  Johannes Krisam^1,11  Jacek Stermann^1,11  Dirk Jäger^1,12  Niels Halama^1,12  Carine Djuka Fokou^1,13  Martin Bornhäuser^1,14 

[1] Charité University Medicine, Berlin, Germany;Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg, Germany;Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany;Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany;Department of Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany;Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany;Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany;Division of Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany;Division of Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany;Division of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany;Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany;Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany;Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany;NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany;University Hospital Dresden, Dresden, Germany;

关键词: COVID-19;    Randomised controlled trial;    protocol;    convalescent plasma;    early application;    high-risk patients with severe disease;   

DOI  :  10.1186/s13063-020-04735-y

来源: Springer

【 授权许可】

CC BY